Biodexa reports 12 month survival in magic-g1 study of mtx110 in recurrent glioblastoma patients

Biodexa pharmaceuticals plc biodexa reports 12 month survival in magic-g1 study of mtx110 in recurrent glioblastoma patients cardiff, united kingdom, february 8, 2024 (globe newswire) -- biodexa pharmaceuticals plc (“biodexa” or the “company”) (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including type 1 diabetes and rare/orphan brain cancers, today provided survival updates from its magic-g1 study (nct05324501) of mtx110 in patients with recurrent glioblastoma (“rgbm”) being conducted at duke cancer institute and baptist md anderson cancer center. in october 2023, biodexa announced completion of recruitment of cohort a of an ongoing open-label phase i dose-escalation study designed to assess the feasibility and safety of intermittent infusions of mtx110 administered by convection enhanced delivery (“ced”) via implanted refillable pump and catheter.
BDRX Ratings Summary
BDRX Quant Ranking